(GSK) GlaxoSmithKline - Ratings and Ratios
Vaccines, Specialty Medicines, General Medicines, Respiratory, Oncology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.20% |
| Yield on Cost 5y | 5.36% |
| Yield CAGR 5y | -11.31% |
| Payout Consistency | 90.9% |
| Payout Ratio | 37.4% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 24.7% |
| Value at Risk 5%th | 38.1% |
| Relative Tail Risk | -6.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.48 |
| Alpha | 43.45 |
| CAGR/Max DD | 0.56 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.384 |
| Beta | 0.231 |
| Beta Downside | 0.148 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.46% |
| Mean DD | 8.41% |
| Median DD | 6.88% |
Description: GSK GlaxoSmithKline December 03, 2025
GSK plc (NYSE:GSK) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the UK, US, and global markets, organized into Commercial Operations and Total R&D segments. Its specialty portfolio spans oncology, respiratory-immunology, inflammation, and HIV-related inhaled therapies, while its vaccine suite includes products for shingles, RSV, seasonal flu, HPV, and a broad range of pediatric and adult diseases. The firm also supplies general medicines for asthma, COPD, bacterial infections, BPH, allergic rhinitis, and inflammatory skin conditions.
Key recent metrics: FY2023 revenue was $46.8 billion, with a dividend yield near 5.5 % and a payout ratio of ~70 %, reflecting its status as a high-yielding pharma dividend. R&D intensity remains high, with ~12 % of sales reinvested in research (≈$5.6 billion in FY2023), supporting a pipeline that includes the RSV vaccine candidate (RSVpreF) and several oncology assets in Phase III trials. A primary sector driver is the aging global population, which sustains demand for vaccines and chronic-disease therapeutics, while pricing pressures from health-care payers and inflationary cost environments introduce earnings volatility.
Strategic collaborations include an mRNA vaccine partnership with CureVac and an alliance with AN2 Therapeutics to develop new tuberculosis therapies, both aimed at diversifying GSK’s pipeline beyond its traditional small-molecule and protein-based products.
For a deeper dive into GSK’s valuation metrics and peer comparisons, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 5.49b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.94 > 1.0 |
| NWC/Revenue: -14.62% < 20% (prev -13.29%; Δ -1.33% < -1%) |
| CFO/TA 0.10 > 3% & CFO 8.60b > Net Income 5.49b |
| Net Debt (19.46b) to EBITDA (10.80b): 1.80 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.05b) vs 12m ago 0.54% < -2% |
| Gross Margin: 72.27% > 18% (prev 0.72%; Δ 7156 % > 0.5%) |
| Asset Turnover: 45.75% > 50% (prev 53.94%; Δ -8.19% > 0%) |
| Interest Coverage Ratio: 11.68 > 6 (EBITDA TTM 10.80b / Interest Expense TTM 657.0m) |
Altman Z'' 1.18
| A: -0.06 (Total Current Assets 24.02b - Total Current Liabilities 28.72b) / Total Assets 82.58b |
| B: 0.16 (Retained Earnings 13.48b / Total Assets 82.58b) |
| C: 0.11 (EBIT TTM 7.67b / Avg Total Assets 70.31b) |
| D: 0.28 (Book Value of Equity 17.05b / Total Liabilities 61.37b) |
| Altman-Z'' Score: 1.18 = BB |
Beneish M -2.65
| DSRI: 1.47 (Receivables 11.18b/7.38b, Revenue 32.17b/31.31b) |
| GMI: 0.99 (GM 72.27% / 71.55%) |
| AQI: 1.02 (AQ_t 0.54 / AQ_t-1 0.53) |
| SGI: 1.03 (Revenue 32.17b / 31.31b) |
| TATA: -0.04 (NI 5.49b - CFO 8.60b) / TA 82.58b) |
| Beneish M-Score: -2.65 = A |
ValueRay F-Score (Strict, 0-100) 76.90
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 6.30% |
| 3. FCF Margin: 18.51% |
| 4. Debt/Equity: 1.10 |
| 5. Debt/Ebitda: 1.80 |
| 6. ROIC - WACC: 30.62% |
| 7. RoE: 29.72% |
| 8. Revenue Trend: 19.29% |
| 9. EPS Trend: -12.33% |
What is the price of GSK shares?
Over the past week, the price has changed by -0.96%, over one month by +0.12%, over three months by +10.88% and over the past year by +51.78%.
Is GSK a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the GSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50 | 2.7% |
| Analysts Target Price | 50 | 2.7% |
| ValueRay Target Price | 58 | 19.1% |
GSK Fundamental Data Overview January 17, 2026
P/E Trailing = 13.7207
P/E Forward = 9.4877
P/S = 3.0863
P/B = 4.5652
P/EG = 0.4218
Revenue TTM = 32.17b GBP
EBIT TTM = 7.67b GBP
EBITDA TTM = 10.80b GBP
Long Term Debt = 14.89b GBP (from longTermDebt, last quarter)
Short Term Debt = 3.84b GBP (from shortTermDebt, last quarter)
Debt = 23.90b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.46b GBP (from netDebt column, last quarter)
Enterprise Value = 94.50b GBP (73.90b + Debt 23.90b - CCE 3.30b)
Interest Coverage Ratio = 11.68 (Ebit TTM 7.67b / Interest Expense TTM 657.0m)
EV/FCF = 15.87x (Enterprise Value 94.50b / FCF TTM 5.95b)
FCF Yield = 6.30% (FCF TTM 5.95b / Enterprise Value 94.50b)
FCF Margin = 18.51% (FCF TTM 5.95b / Revenue TTM 32.17b)
Net Margin = 17.08% (Net Income TTM 5.49b / Revenue TTM 32.17b)
Gross Margin = 72.27% ((Revenue TTM 32.17b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Gross Margin QoQ = 73.58% (prev 72.89%)
Tobins Q-Ratio = 1.14 (Enterprise Value 94.50b / Total Assets 82.58b)
Interest Expense / Debt = 0.70% (Interest Expense 167.0m / Debt 23.90b)
Taxrate = 12.70% (312.0m / 2.46b)
NOPAT = 6.70b (EBIT 7.67b * (1 - 12.70%))
Current Ratio = 0.84 (Total Current Assets 24.02b / Total Current Liabilities 28.72b)
Debt / Equity = 1.10 (Debt 23.90b / totalStockholderEquity, last quarter 21.74b)
Debt / EBITDA = 1.80 (Net Debt 19.46b / EBITDA 10.80b)
Debt / FCF = 3.27 (Net Debt 19.46b / FCF TTM 5.95b)
Total Stockholder Equity = 18.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 5.49b / Total Assets 82.58b)
RoE = 29.72% (Net Income TTM 5.49b / Total Stockholder Equity 18.49b)
RoCE = 22.98% (EBIT 7.67b / Capital Employed (Equity 18.49b + L.T.Debt 14.89b))
RoIC = 35.88% (NOPAT 6.70b / Invested Capital 18.66b)
WACC = 5.26% (E(73.90b)/V(97.80b) * Re(6.77%) + D(23.90b)/V(97.80b) * Rd(0.70%) * (1-Tc(0.13)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.19%
[DCF Debug] Terminal Value 83.94% ; FCFF base≈5.93b ; Y1≈4.80b ; Y5≈3.34b
Fair Price DCF = 41.17 (EV 102.50b - Net Debt 19.46b = Equity 83.04b / Shares 2.02b; r=5.90% [WACC]; 5y FCF grow -22.74% → 2.90% )
EPS Correlation: -12.33 | EPS CAGR: -47.24% | SUE: -4.0 | # QB: 0
Revenue Correlation: 19.29 | Revenue CAGR: -2.85% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.27 | Chg30d=+0.080 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=4.74 | Chg30d=+0.089 | Revisions Net=+2 | Growth EPS=+8.8% | Growth Revenue=+4.9%
Additional Sources for GSK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle